MetLife Investment Management LLC Has $3.31 Million Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

MetLife Investment Management LLC raised its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 82.6% in the 3rd quarter, HoldingsChannel reports. The fund owned 9,900 shares of the medical research company’s stock after buying an additional 4,478 shares during the quarter. MetLife Investment Management LLC’s holdings in Bio-Rad Laboratories were worth $3,312,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Avior Wealth Management LLC grew its position in shares of Bio-Rad Laboratories by 3.3% during the 3rd quarter. Avior Wealth Management LLC now owns 999 shares of the medical research company’s stock worth $334,000 after buying an additional 32 shares during the period. UMB Bank n.a. grew its position in shares of Bio-Rad Laboratories by 140.6% during the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after buying an additional 45 shares during the period. Capital Advisors Ltd. LLC grew its position in shares of Bio-Rad Laboratories by 193.8% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after buying an additional 62 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in shares of Bio-Rad Laboratories by 9.5% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 947 shares of the medical research company’s stock worth $259,000 after buying an additional 82 shares during the period. Finally, GAMMA Investing LLC grew its position in shares of Bio-Rad Laboratories by 37.2% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical research company’s stock worth $88,000 after buying an additional 87 shares during the period. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Down 1.9 %

Shares of BIO opened at $332.28 on Wednesday. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16. Bio-Rad Laboratories, Inc. has a twelve month low of $262.12 and a twelve month high of $387.99. The firm’s 50 day moving average price is $341.01 and its two-hundred day moving average price is $318.35.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The firm had revenue of $649.70 million for the quarter, compared to analyst estimates of $628.18 million. During the same quarter in the previous year, the firm posted $2.33 earnings per share. The business’s revenue was up 2.8% on a year-over-year basis. As a group, research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.29 earnings per share for the current year.

Analysts Set New Price Targets

BIO has been the subject of a number of analyst reports. StockNews.com upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Citigroup boosted their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Royal Bank of Canada boosted their price objective on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Finally, Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price objective for the company. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Bio-Rad Laboratories has an average rating of “Moderate Buy” and a consensus price target of $391.80.

Insider Transactions at Bio-Rad Laboratories

In other news, COO Andrew J. Last sold 3,000 shares of the business’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the sale, the chief operating officer now owns 7,559 shares of the company’s stock, valued at $2,494,016.46. The trade was a 28.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 17.50% of the stock is currently owned by insiders.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.